Table 2.
SDRM prevalence by year
| Overall | 2009–2010 | 2011–2012 | 2013–2014 | p | |
|---|---|---|---|---|---|
| N enrolled | 229 | 32 | 52 | 145 | – |
| Any resistance, n (%) | 16 (7.0) | 4 (12.5) | 5 (9.6) | 7 (4.8) | 0.08 |
| N with RT genotype | 228 | 32 | 51 | 145 | – |
| NRTI | 6 (2.6) | 2 (6.3) | 2 (3.9) | 2 (1.4) | 0.09 |
| NNRTI | 5 (2.2) | 3 (9.4) | 1 (2.0) | 1 (0.7) | 0.01 |
| N with PR genotype | 225 | 32 | 50 | 143 | – |
| PI | 8 (3.6) | 1 (3.1) | 3 (6.0) | 4 (2.8) | 0.64 |
RT, reverse transcriptase; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PR, protease region; PI, protease inhibitor.